Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01606761




Registration number
NCT01606761
Ethics application status
Date submitted
24/05/2012
Date registered
28/05/2012
Date last updated
23/03/2018

Titles & IDs
Public title
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy
Secondary ID [1] 0 0
CNTO136ARA3003
Secondary ID [2] 0 0
CR100864
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - Sirukumab
Treatment: Drugs - Sirukumab
Treatment: Drugs - Sirukumab

Experimental: Group 1 - Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.

Experimental: Group 2 - Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.

Experimental: Group 3 - Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.


Treatment: Drugs: Placebo
Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.

Treatment: Drugs: Placebo
Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.

Treatment: Drugs: Sirukumab
Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.

Treatment: Drugs: Sirukumab
Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.

Treatment: Drugs: Sirukumab
Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Response at Week 24
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Percentage of Participants With Disease Activity Index Score 28 (CRP) Remission at Week 24
Timepoint [3] 0 0
Week 24

Eligibility
Key inclusion criteria
* Have a diagnosis of rheumatoid arthritis (RA) for at least 3 months before screening
* Have moderately to severely active RA with at least 4 of 68 tender joints and 4 of 66 swollen joints, at screening and at baseline
* Have had anti-tumor necrosis factor (TNF)-alpha therapy and were unresponsive by 1 of the following 2 reasons: Lack of benefit to at least 1 anti-TNF-alpha biologic therapy, as assessed by the treating physician, after at least 12 weeks of etanercept, yisaipu, adalimumab, golimumab, or certolizumab pegol therapy and/or at least a 14-week dosage regimen (ie, at least 4 doses) of infliximab; Intolerance to at least 2 anti-TNF-alpha biologic therapies, as assessed by the treating physician, to etanercept, yisaipu, adalimumab, golimumab, certolizumab pegol, or infliximab or have documented intolerance to an anti-TNF-alpha agent as described above that precludes further administration of anti-TNF-alpha agents
* If using oral corticosteroids, must be on a stable dose equivalent to less than or equal to 10 mg/day of prednisone for at least 2 weeks prior to the first administration of study agent. If currently not using corticosteroids, must not have received oral corticosteroids for at least 2 weeks prior to the first administration of study agent
* If using non nonsteroidal anti-inflammatory drug (NSAIDs) or other analgesics for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent
* If using non-biologic disease modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine, chloroquine, or bucillamine, must be on a stable dose for at least 4 weeks prior to the first administration of study agent and should have no serious toxic side effects attributable to the DMARD
* C-reactive protein (CRP) 8.00 mg/L or more or erythrocyte sedimentation rate (ESR) 28 mm/hr or more at screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has received infliximab, infliximab biosimilar, or golimumab intravenous (IV) within 8 weeks of the first study agent administration
* Has received subcutaneously (SC) golimumab, adalimumab, or certolizumab pegol within 6 weeks of the first study agent administration
* Has received etanercept or yisaipu within 4 weeks of the first study agent administration
* Has a history of intolerance to tocilizumab that precluded further treatment with it, or inadequate response to 3 months of tocilizumab (anti-IL-6 receptor) therapy. Has used tocilizumab within 8 weeks of the first study agent administration
* Has used B-cell-depleting therapy (eg, rituximab) within 7 months of first study agent administration or have evidence during screening of abnormally low B-cell level caused by previous B-cell depletion therapy
* Has used anakinra within 1 week of first study agent administration
* Has used abatacept or any other biologic therapy for the treatment of RA within 8 weeks of the first study agent administration
* Has received intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA, including adrenocorticotrophic hormone during the 4 weeks prior to first study agent administration
* Has received leflunomide within 24 months before the first study agent administration and has not undergone a drug elimination procedure, unless the M1 metabolite is measured and is undetectable
* Has a history of cyclophosphamide or cytotoxic agent use
* Has received cyclosporine A, azathioprine, tacrolimus, mycophenolate mofetil, oral or parenteral gold, or D-penicillamine within 4 weeks of the first study agent administration
* Has received an investigational drug (including investigational vaccines) or used an investigational medical device within 3 months or 5 half-lives, whichever is longer, before the first study agent administration

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/08/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/01/2016
Sample size
Target
Accrual to date
Final
878
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Campbelltown
Recruitment hospital [2] 0 0
- Victoria Park
Recruitment postcode(s) [1] 0 0
- Campbelltown
Recruitment postcode(s) [2] 0 0
- Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oklahoma
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Rhode Island
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
Argentina
State/province [29] 0 0
Ciudad Autónoma De Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Rosario
Country [31] 0 0
Argentina
State/province [31] 0 0
San Miguel De Tucuman
Country [32] 0 0
Austria
State/province [32] 0 0
Vienna
Country [33] 0 0
Austria
State/province [33] 0 0
Wien
Country [34] 0 0
Belgium
State/province [34] 0 0
Liège
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Manitoba
Country [37] 0 0
Canada
State/province [37] 0 0
Newfoundland and Labrador
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Burlington
Country [40] 0 0
Canada
State/province [40] 0 0
Saint-John'S
Country [41] 0 0
Canada
State/province [41] 0 0
Toronto N/A
Country [42] 0 0
Croatia
State/province [42] 0 0
Zagreb
Country [43] 0 0
France
State/province [43] 0 0
Paris
Country [44] 0 0
France
State/province [44] 0 0
Toulouse Cedex 9
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Germany
State/province [46] 0 0
Dresden
Country [47] 0 0
Germany
State/province [47] 0 0
Erfurt
Country [48] 0 0
Germany
State/province [48] 0 0
Frankfurt/Main
Country [49] 0 0
Germany
State/province [49] 0 0
Gÿttingen N/A
Country [50] 0 0
Germany
State/province [50] 0 0
Hamburg
Country [51] 0 0
Germany
State/province [51] 0 0
Herne
Country [52] 0 0
Germany
State/province [52] 0 0
Kiel Kronshagen
Country [53] 0 0
Germany
State/province [53] 0 0
Köln
Country [54] 0 0
Germany
State/province [54] 0 0
Schwerin
Country [55] 0 0
Germany
State/province [55] 0 0
Vogelsang-Gommern
Country [56] 0 0
Germany
State/province [56] 0 0
Würzburg
Country [57] 0 0
Germany
State/province [57] 0 0
Zerbst
Country [58] 0 0
Japan
State/province [58] 0 0
Ayauta
Country [59] 0 0
Japan
State/province [59] 0 0
Bunkyo-Ku
Country [60] 0 0
Japan
State/province [60] 0 0
Fukuoka
Country [61] 0 0
Japan
State/province [61] 0 0
Fukuyama
Country [62] 0 0
Japan
State/province [62] 0 0
Higashihiroshima
Country [63] 0 0
Japan
State/province [63] 0 0
Hiroshima
Country [64] 0 0
Japan
State/province [64] 0 0
Izumo
Country [65] 0 0
Japan
State/province [65] 0 0
Kagoshima
Country [66] 0 0
Japan
State/province [66] 0 0
Kato
Country [67] 0 0
Japan
State/province [67] 0 0
Kawagoe
Country [68] 0 0
Japan
State/province [68] 0 0
Kita-Gun
Country [69] 0 0
Japan
State/province [69] 0 0
Kumamoto
Country [70] 0 0
Japan
State/province [70] 0 0
Kurume
Country [71] 0 0
Japan
State/province [71] 0 0
Matsuyama
Country [72] 0 0
Japan
State/province [72] 0 0
Miyazaki
Country [73] 0 0
Japan
State/province [73] 0 0
Nagano
Country [74] 0 0
Japan
State/province [74] 0 0
Nagasaki
Country [75] 0 0
Japan
State/province [75] 0 0
Nagoya
Country [76] 0 0
Japan
State/province [76] 0 0
Nishimuro-Gun
Country [77] 0 0
Japan
State/province [77] 0 0
Nishinomiya
Country [78] 0 0
Japan
State/province [78] 0 0
Okayama
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka
Country [80] 0 0
Japan
State/province [80] 0 0
Sapporo
Country [81] 0 0
Japan
State/province [81] 0 0
Sasebo
Country [82] 0 0
Japan
State/province [82] 0 0
Shibata
Country [83] 0 0
Japan
State/province [83] 0 0
Shimonoseki
Country [84] 0 0
Japan
State/province [84] 0 0
Shimotsuke
Country [85] 0 0
Japan
State/province [85] 0 0
Shinjuku-Ku
Country [86] 0 0
Japan
State/province [86] 0 0
Sumida-Ku
Country [87] 0 0
Japan
State/province [87] 0 0
Takaoka,Toyama
Country [88] 0 0
Japan
State/province [88] 0 0
Takasaki
Country [89] 0 0
Japan
State/province [89] 0 0
Tokorozawa
Country [90] 0 0
Japan
State/province [90] 0 0
Tokushima
Country [91] 0 0
Japan
State/province [91] 0 0
Tomakomai
Country [92] 0 0
Japan
State/province [92] 0 0
Tomishiro
Country [93] 0 0
Japan
State/province [93] 0 0
Tonami
Country [94] 0 0
Japan
State/province [94] 0 0
Tsu
Country [95] 0 0
Japan
State/province [95] 0 0
Ureshino
Country [96] 0 0
Japan
State/province [96] 0 0
Yokohama
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Busan
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Daegu
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Daejeon
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Gwangju
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Incheon
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Jeonju-Si
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Seongnam-Si
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Seoul
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Suwon
Country [106] 0 0
Lithuania
State/province [106] 0 0
Kaunas
Country [107] 0 0
Lithuania
State/province [107] 0 0
Klaipeda
Country [108] 0 0
Mexico
State/province [108] 0 0
Guadalajara
Country [109] 0 0
Mexico
State/province [109] 0 0
Merida
Country [110] 0 0
Mexico
State/province [110] 0 0
San Luis Potosí
Country [111] 0 0
Netherlands
State/province [111] 0 0
Sneek
Country [112] 0 0
New Zealand
State/province [112] 0 0
Christchurch
Country [113] 0 0
New Zealand
State/province [113] 0 0
Hamilton
Country [114] 0 0
New Zealand
State/province [114] 0 0
Wellington
Country [115] 0 0
Poland
State/province [115] 0 0
Bydgoszcz
Country [116] 0 0
Poland
State/province [116] 0 0
Elblag
Country [117] 0 0
Poland
State/province [117] 0 0
Lublin
Country [118] 0 0
Poland
State/province [118] 0 0
Poznan
Country [119] 0 0
Poland
State/province [119] 0 0
Ustron
Country [120] 0 0
Poland
State/province [120] 0 0
Warszawa
Country [121] 0 0
Portugal
State/province [121] 0 0
Coimbra
Country [122] 0 0
Portugal
State/province [122] 0 0
Lisboa
Country [123] 0 0
Portugal
State/province [123] 0 0
Lisbon
Country [124] 0 0
Puerto Rico
State/province [124] 0 0
San Juan
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Barnaul
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Moscow N/A
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Moscow
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Novosibirsk
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Omsk
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Orenburg
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Ryazan
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Saint Petersburg
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Saratov
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Ulyanovsk
Country [135] 0 0
Spain
State/province [135] 0 0
Bilbao
Country [136] 0 0
Spain
State/province [136] 0 0
Coruña
Country [137] 0 0
Spain
State/province [137] 0 0
La Laguna
Country [138] 0 0
Spain
State/province [138] 0 0
Madrid
Country [139] 0 0
Spain
State/province [139] 0 0
Mérida
Country [140] 0 0
Spain
State/province [140] 0 0
Santander
Country [141] 0 0
Spain
State/province [141] 0 0
Santiago De Compostela
Country [142] 0 0
Taiwan
State/province [142] 0 0
Kaohsiung
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taichung City
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taichung
Country [145] 0 0
Taiwan
State/province [145] 0 0
Taipei
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Barnsley
Country [147] 0 0
United Kingdom
State/province [147] 0 0
London
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Middlesbrough
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Sheffield
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Wigan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
GlaxoSmithKline
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with anti-TNF-alpha agents.
Trial website
https://clinicaltrials.gov/study/NCT01606761
Trial related presentations / publications
Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017 Mar 25;389(10075):1206-1217. doi: 10.1016/S0140-6736(17)30401-4. Epub 2017 Feb 16. Erratum In: Lancet. 2017 May 20;389(10083):1980. doi: 10.1016/S0140-6736(17)31299-0.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01606761